CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 890 participants.

Also called NCT06994975

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 890 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06994975
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06994975. Randomized; single masking; primary purpose treatment. Start 2025-11-03 (actual); primary completion 2028-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection
Acronym
CHESTNUT
Condition
Acute Ischemic Stroke
Intervention (Drug)
0.25mg/kg TNK
Intervention (Drug)
Standard medical treatment
Lead sponsor
Huashan Hospital (class: other)

Record details

Record id
cardio:ct-nct06994975
Content hash
f77909d1d2ddbe3a8f32d67a7d2c8ef7a5cd48906ea9c00dfd2cf8dd1e87b6e5